Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Traws Pharma Inc TRAW

Healthcare
Traws Pharma, Inc., formerly Onconova Therapeutics, Inc., is a virology and oncology company. The Company is engaged in developing antivirals for influenza, COVID and other respiratory infections and narazaciclib. Its proprietary portfolio includes, TRX100 (viroksavir), TRX01 (travaltrevir), and Narazaciclib. Viroksavir is a cap-dependent endonuclease inhibitor for influenza. Travaltrevir is a... see more

Recent & Breaking News (NDAQ:TRAW)

Onconova Therapeutics to Participate in Ladenburg Thalmann Virtual R&D Showcase on Narazaciclib in Endometrial Cancer

GlobeNewswire May 12, 2023

Onconova Therapeutics Doses First Patient in Phase 1/2a Trial of Narazaciclib Combined with Letrozole in Endometrial Cancer

GlobeNewswire May 11, 2023

Onconova Therapeutics to Present at the ISID International Epidermolysis Bullosa Symposium

GlobeNewswire May 8, 2023

Onconova Therapeutics to Provide Corporate Update and Announce First Quarter 2023 Financial Results on May 15, 2023

GlobeNewswire May 4, 2023

Onconova Therapeutics Announces the Presentation of New Preclinical Data on Narazaciclib at the AACR Annual Meeting

GlobeNewswire April 19, 2023

Onconova Therapeutics Announces the Unexpected Passing of Chief Medical Officer Dr. Mark Gelder

GlobeNewswire April 6, 2023

Onconova Therapeutics and Pangea Biomed Enter into Research Collaboration to Identify Biomarkers of Response to Rigosertib

GlobeNewswire March 23, 2023

Onconova Therapeutics Reports Full Year 2022 Financial Results and Provides Business Update

GlobeNewswire March 16, 2023

Onconova Therapeutics Announces Upcoming Poster Presentations at the AACR Annual Meeting

GlobeNewswire March 15, 2023

Onconova Therapeutics to Provide Corporate Update and Announce Fourth Quarter and Full Year 2022 Financial Results on March 16, 2023

GlobeNewswire March 9, 2023

Onconova Therapeutics Presents Preclinical Data Characterizing Rigosertib's Mechanisms of Action at the AACR Targeting RAS Conference

GlobeNewswire March 7, 2023

Onconova Therapeutics Announces Additional Clinical Data Demonstrating Rigosertib's Monotherapy Activity in RDEB-Associated Squamous Cell Carcinoma

GlobeNewswire February 7, 2023

Onconova Therapeutics to Present at the 2023 Guggenheim Oncology Conference

GlobeNewswire February 1, 2023

Onconova Therapeutics Announces Participation in the Channelchek Takeaway Series

GlobeNewswire January 26, 2023

Onconova Therapeutics Appoints Drs. Peter Atadja and Trafford Clarke to its Board of Directors

GlobeNewswire December 19, 2022

Onconova Therapeutics to Present at the Upcoming MedInvest Oncology Investor Conference

GlobeNewswire December 7, 2022

Onconova Therapeutics to Present at the Upcoming RHK Capital Disruptive Growth Conference

GlobeNewswire November 28, 2022

Onconova Therapeutics Announces Plans for a Phase 1/2a Trial of Narazaciclib Combined with Letrozole in Endometrial Cancer, Reports Third Quarter 2022 Financial Results, and Provides a Business Update

GlobeNewswire November 14, 2022

Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter Financial Results on November 14, 2022

GlobeNewswire November 7, 2022

Onconova Therapeutics to Present at the Ladenburg Thalmann 2022 Healthcare Conference

GlobeNewswire September 22, 2022